NYSE · Financial Statements
Haemonetics Corporation (HAE) Financial Statements
$118.28
NYSE: HAE
Market Cap $5.38B
Overview Financials Dividend
Haemonetics Corporation most recently reported annual revenue of $1.3B, net profit of $97.0M. Revenue grew at an average annual rate of 8.9% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2022 2023 2024 2025 2026
Revenue $993.0M $1.2B $1.3B $1.4B $1.3B Operating Profit $81.0M $156.0M $165.0M $222.0M $241.0M Net Profit $43.0M $115.0M $118.0M $168.0M $97.0M EPS $0.84 $2.24 $2.29 $3.31 $2.05 Op Margin 8.1% 13.3% 12.6% 16.3% 18.1%
Balance Sheet (USD)
Metric 2022 2023 2024 2025 2026
Total Assets $1.9B $1.9B $2.2B $2.5B $2.4B Total Liabilities $1.1B $1.1B $1.2B $1.6B $1.6B Cash $259.0M $284.0M $179.0M $307.0M $245.0M Borrowings $781.0M $766.0M $808.0M $1.2B $1.2B
Cash Flow (USD)
Metric 2022 2023 2024 2025 2026
Operating Cash Flow $172.0M $273.0M $182.0M $182.0M $293.0M Investing Cash Flow $-183.0M $-254.0M $-361.0M $-201.0M $-212.0M Financing Cash Flow $-5.0M $-91.0M $-1.0M $-337.0M $-180.0M Net Cash Flow $67.0M $25.0M $-106.0M $128.0M $-61.0M Free Cash Flow $76.0M $163.0M $144.0M $142.0M $260.0M
Valuation & Return Ratios
Metric Value PEG Ratio -1.35 EV / EBITDA 21.79 FCF Yield 6.14% Quick Ratio 1.91 Interest Coverage 8.03 Return 1Y 92.94% Return 3Y 13.92% Return 5Y 59.21%
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .